ClearOne to acquire Cortigent from Vivani Medical in stock deal; plans $10-15M financing

CLEARONE INC

ClearOne (CLRO) will issue 12.5M shares to Vivani (VANI) for Cortigent, a neurostimulation firm.
Concurrent S-1 registration to raise $10M-$15M via units of common stock and warrants.
Post-closing board set at 5 members: Adam Mendelsohn (Chair), Jonathan Adams, John Bowers, Linda Szyper, Eric Robinson.
Jonathan Adams to be President & CEO; Ed Sedo CFO; Rachel Evans Corporate Secretary.
Closing conditions include stockholder approvals, financing completion, and Nasdaq continued listing; 180-day termination right.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.